Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 9/20 | 0.66 |
| ▸ | LMNA | P02545 | 4/20 | 0.66 |
| ▸ | HTT | P42858 | 2/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.66 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.50 |
| ▸ | KIF11 | P52732 | 1/20 | 0.50 |
| ▸ | AR | P10275 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.44 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | PGR | P06401 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9835864 | 0.87 | HPGD (0.50) | HPGDLMNAHTTSMN1; SMN2MAPT | |
| SCHEMBL3063965 | 0.83 | HPGD (0.55) | HPGDLMNAHTTSMN1; SMN2MAPT | |
| SCHEMBL3061132 | 0.82 | HPGD (0.44) | HPGDLMNAHTTSMN1; SMN2MAPT | |
| SCHEMBL3070158 | 0.82 | GRIA4 (0.47) | HPGDLMNAHTTSMN1; SMN2MAPT | |
| SCHEMBL12678665 | 0.81 | HPGD (0.56) | HPGDLMNAHTTSMN1; SMN2MAPT | |
| SCHEMBL5332931 | 0.80 | HPGD (0.60) | HPGDLMNAHTTSMN1; SMN2MAPT | |
| SCHEMBL394895 | 0.79 | ALDH1A1 (0.61) | HPGDLMNAHTTSMN1; SMN2MAPT | |
| SCHEMBL6798952 | 0.78 | PGR (0.46) | HPGDLMNAHTTSMN1; SMN2MAPT | |
| SCHEMBL9654379 | 0.78 | HPGD (0.49) | HPGDLMNAHTTSMN1; SMN2MAPT | |
| SCHEMBL9054541 | 0.77 | HPGD (0.67) | HPGDLMNAHTTSMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066358-A1 | Inhibitors of Menin-MLL Interaction | BALA THERAPEUTICS, INC. | 2025-02-27 | — | — | US | disclosed |
| EP-4444313-A1 | INHIBITORS OF MENIN-MLL INTERACTION | Bala Therapeutics, Inc. (US) | 2024-10-16 | — | — | EP | disclosed |
| WO-2023107687-A1 | INHIBITORS OF MENIN-MLL INTERACTION | BALA THERAPEUTICS, INC. (US) | 2023-06-15 | — | — | WO | disclosed |
| US-8551999-B2 | Heterocyclic compound and pharmaceutical composition thereof | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-10-08 | — | — | US | disclosed |
| EP-2207773-B1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF | OTSUKA PHARMA CO LTD (JP) | 2012-07-11 | — | — | EP | disclosed |
| US-20100261720-A1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-10-14 | — | — | US | disclosed |
| EP-2207773-A2 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF | Otsuka Pharmaceutical Co., Ltd. (JP) | 2010-07-21 | — | — | EP | disclosed |
| WO-2009057811-A2 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-05-07 | — | — | WO | disclosed |
| EP-0967517-B1 | A dye and silver halide photographic light sensitive material containing a fine solid particle dispersion of said dye | KONISHIROKU PHOTO IND (JP) | 2004-01-02 | — | — | EP | disclosed |
| US-6187929-B1 | NONDIFFUSIBLE DYE PROVIDING HIGH SPEED SILVER HALIDE PHOTOGRAPHIC LIGHT SENSITIVE MATERIAL WITH REDUCED FOG FORMATION AND IMPROVED STABILITY WITH PASSAGE OF TIME | KONICA CORPORATION (JP) | 2001-02-13 | — | — | US | disclosed |
| US-5998117-A | METHINE DYE CAPABLE OF BEING DECOLORED BY REACTING WITH A COLOR DEVELOPING AGENT. | KONICA CORPORATION (JP) | 1999-12-07 | — | — | US | disclosed |
| EP-0795780-A1 | Silver halide photographic light-sensitive material | KONICA CORPORATION (JP) | 1997-09-17 | — | — | EP | disclosed |
| EP-0401709-B1 | X-ray photographic material | FUJI PHOTO FILM CO LTD (JP) | 1995-12-27 | — | — | EP | disclosed |
| US-5147769-A | Image sharpness | FUJI PHOTO FILM CO., LTD. (JP) | 1992-09-15 | — | — | US | disclosed |
| EP-0215124-B1 | SILVER HALIDE PHOTOGRAPHIC PHOTO-SENSITIVE MATERIAL | FUJI PHOTO FILM CO., LTD. (JP) | 1991-09-04 | — | — | EP | disclosed |
| US-4925782-A | Silver halide photographic light-sensitive element containing water soluble dye compounds | FUJI PHOTO FILM CO., LTD. (JP) | 1990-05-15 | — | — | US | disclosed |
| US-4879204-A | HIGH CONTRAST | FUJI PHOTO FILM CO., LTD. (JP) | 1989-11-07 | — | — | US | disclosed |
| EP-0319999-A2 | Silver halide photographic materials | Fuji Photo Film Co., Ltd. (JP) | 1989-06-14 | — | — | EP | disclosed |
| US-4764455-A | Color image-forming process | FUJI PHOTO FILM CO., LTD. (JP) | 1988-08-16 | — | — | US | disclosed |
| EP-0215124-A1 | SILVER HALIDE PHOTOGRAPHIC PHOTO-SENSITIVE MATERIAL | FUJI PHOTO FILM CO., LTD. (JP) | 1987-03-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261720-A1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF | COL1A1, COL2A1, COL14A1 | HPGD 263/4885LMNA 1184/4885HTT 1225/4885 |
| US-20250066358-A1 | Inhibitors of Menin-MLL Interaction | MLLT1, MEN1, BMI1 | HPGD 2981/4885LMNA 531/4885HTT 3578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.